International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
Although the threshold of cost effectiveness of medical interventions is thought to be £20 000–£30 000 in the UK, and $50 000–$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness‐to‐pay (WTP) for one additional q...
Saved in:
| Published in | Health economics Vol. 19; no. 4; pp. 422 - 437 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chichester, UK
John Wiley & Sons, Ltd
01.04.2010
Wiley-Blackwell Wiley Periodicals Inc |
| Series | Health Economics |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1057-9230 1099-1050 1099-1050 |
| DOI | 10.1002/hec.1481 |
Cover
| Abstract | Although the threshold of cost effectiveness of medical interventions is thought to be £20 000–£30 000 in the UK, and $50 000–$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness‐to‐pay (WTP) for one additional quality‐adjusted life‐year gained to determine the threshold of the incremental cost‐effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double‐bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), £23 000 (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost‐effectiveness plane and methodology for decision making. Copyright © 2009 John Wiley & Sons, Ltd. |
|---|---|
| AbstractList | Although the threshold of cost effectiveness of medical interventions is thought to be £20 000–£30 000 in the UK, and $50 000–$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness‐to‐pay (WTP) for one additional quality‐adjusted life‐year gained to determine the threshold of the incremental cost‐effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double‐bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), £23 000 (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost‐effectiveness plane and methodology for decision making. Copyright © 2009 John Wiley & Sons, Ltd. Although the threshold of cost effectiveness of medical interventions is thought to be 20 000- 30 000 UK pounds in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), 23 000 UK pounds (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making.Although the threshold of cost effectiveness of medical interventions is thought to be 20 000- 30 000 UK pounds in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), 23 000 UK pounds (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making. Although the threshold of cost effectiveness of medical interventions is thought to be L20 000-L30 000 in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), L23 000 (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making. [PUBLICATION ABSTRACT] Although the threshold of cost effectiveness of medical interventions is thought to be (pound sterling)20 000-(pound sterling)30 000 in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), (pound sterling)23 000 (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making. [Copyright John Wiley and Sons, Ltd.] Although the threshold of cost effectiveness of medical interventions is thought to be 20 000- 30 000 UK pounds in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), 23 000 UK pounds (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making. |
| Author | Fukuda, Takashi Lang, Hui-Chu Sung, Yoon-Kyoung Bae, Sang-Cheol Tsutani, Kiichiro Shiroiwa, Takeru |
| Author_xml | – sequence: 1 givenname: Takeru surname: Shiroiwa fullname: Shiroiwa, Takeru email: t.shiroiwa@gmail.com organization: Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan – sequence: 2 givenname: Yoon-Kyoung surname: Sung fullname: Sung, Yoon-Kyoung organization: Department of Rheumatology, The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea – sequence: 3 givenname: Takashi surname: Fukuda fullname: Fukuda, Takashi organization: Department of Health Economics and Epidemiology Research, School of Public Health, The University of Tokyo, Tokyo, Japan – sequence: 4 givenname: Hui-Chu surname: Lang fullname: Lang, Hui-Chu organization: Institute of Hospital and Health Care Administration, School of Medicine, National Yang-Ming University, Taipei, Taiwan – sequence: 5 givenname: Sang-Cheol surname: Bae fullname: Bae, Sang-Cheol organization: Department of Rheumatology, The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea – sequence: 6 givenname: Kiichiro surname: Tsutani fullname: Tsutani, Kiichiro organization: Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan |
| BackLink | http://www.econis.eu/PPNSET?PPN=634974912$$DView this record in ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften https://www.ncbi.nlm.nih.gov/pubmed/19382128$$D View this record in MEDLINE/PubMed http://econpapers.repec.org/article/wlyhlthec/v_3a19_3ay_3a2010_3ai_3a4_3ap_3a422-437.htm$$DView record in RePEc |
| BookMark | eNqFkktvEzEQx1eoiD5A4hOAxYVy2ODH7jrmgqqoT0W8VFRxshzvbNetsw62k7IHvjteEoKoQBzGY2l-87fnsZ_tdK6DLHtK8IhgTF-3oEekGJMH2R7BQuQEl3hnuJc8F5Th3Ww_hBuMUwxXj7JdItiYEjrey76fdxF8p6JxnbIoLP0KeuQ6dGesNd11ByHk0eUL1aPDq8sPr1DjfIoDUnVtNlkfj6Zf0LUyHdRv0F2rIjIBxRaSeQitszVyDdIuRARNAzqaFQzCbx9nDxtlAzzZ-IPs88nx5eQsn74_PZ8cTXNdMU5SCYLiQjdVyQXTBWVKU1yXRM2U5tWM6UqnwsqSN5ooMZ41RFSKcUa1mgFJxR5kL9e6C---LiFEOTdBg7WqA7cMkheUE1FU_P8kY6ysKk4S-eIeeeOWqZM2SMoorjimg9zFGvKwAC0X3syV7-Wd7VubGqTlSjJFRDr6ZBQTnJxJViRbDJ5SWTAu2zhPYs82Ly5nc6i3ar-mmYDnawC060zYAhUrBC8EoYk4XBPauxA8NL9FsBxWSQ6fGlYpoaN7qDbx555Er4z9W0K-TkirA_0_heXZ8eRP3oQI37a88rcyDYKX8urdqSzpp_EEX5xIwn4Ajork6w |
| CODEN | HEECEZ |
| CitedBy_id | crossref_primary_10_1007_s12160_010_9188_2 crossref_primary_10_3400_avd_oa_17_00059 crossref_primary_10_2165_11597660_000000000_00000 crossref_primary_10_1007_s10198_021_01418_6 crossref_primary_10_1186_1472_6963_14_287 crossref_primary_10_1016_j_lungcan_2015_07_006 crossref_primary_10_1007_s10198_017_0901_y crossref_primary_10_1007_s13555_019_0291_4 crossref_primary_10_3820_jjpe_16_41 crossref_primary_10_1111_jgh_15033 crossref_primary_10_1371_journal_pmed_1002397 crossref_primary_10_1080_13696998_2017_1384383 crossref_primary_10_1016_j_xjon_2023_10_033 crossref_primary_10_1016_j_jval_2016_02_017 crossref_primary_10_1016_j_jval_2016_02_015 crossref_primary_10_1007_s00467_016_3520_4 crossref_primary_10_1016_j_vaccine_2022_01_001 crossref_primary_10_1016_j_jval_2016_02_020 crossref_primary_10_1371_journal_pone_0122760 crossref_primary_10_1186_1472_6963_13_371 crossref_primary_10_1186_s12885_017_3774_7 crossref_primary_10_1007_s00330_021_08356_0 crossref_primary_10_1016_j_jval_2021_05_018 crossref_primary_10_1080_16549716_2018_1447828 crossref_primary_10_1517_17425255_2015_1004053 crossref_primary_10_1298_ptr_E10153 crossref_primary_10_1007_s10384_013_0238_8 crossref_primary_10_1016_j_spinee_2024_12_027 crossref_primary_10_1080_13696998_2018_1532905 crossref_primary_10_1016_j_clinthera_2019_03_011 crossref_primary_10_1007_s13555_022_00744_8 crossref_primary_10_1093_neuros_nyaa077 crossref_primary_10_1186_1471_2458_14_38 crossref_primary_10_1002_jgh3_12597 crossref_primary_10_1016_j_ejso_2016_12_003 crossref_primary_10_1002_pbc_29795 crossref_primary_10_1007_s10198_021_01384_z crossref_primary_10_1186_s40560_023_00708_w crossref_primary_10_21045_2782_1676_2021_1_1_19_31 crossref_primary_10_1007_s00520_012_1397_8 crossref_primary_10_1038_s41598_024_80549_1 crossref_primary_10_2217_pgs_10_74 crossref_primary_10_1080_21645515_2016_1245252 crossref_primary_10_1111_j_1708_8305_2010_00398_x crossref_primary_10_1111_den_14058 crossref_primary_10_1007_s40273_017_0585_2 crossref_primary_10_1016_j_jvs_2014_12_064 crossref_primary_10_1371_journal_pone_0208063 crossref_primary_10_1080_09546634_2020_1744505 crossref_primary_10_1111_cas_15216 crossref_primary_10_1111_poms_12780 crossref_primary_10_1136_bjophthalmol_2020_316880 crossref_primary_10_3390_ijerph19137901 crossref_primary_10_1002_hpm_2313 crossref_primary_10_1185_03007991003689381 crossref_primary_10_1016_j_eururo_2017_03_028 crossref_primary_10_12688_f1000research_11085_1 crossref_primary_10_1253_circj_CJ_17_1455 crossref_primary_10_1016_j_healthpol_2014_07_016 crossref_primary_10_1016_j_jaip_2017_07_028 crossref_primary_10_1111_1346_8138_14876 crossref_primary_10_2196_jmir_4207 crossref_primary_10_2165_11597110_000000000_00000 crossref_primary_10_1002_acr_20338 crossref_primary_10_1111_hepr_13053 crossref_primary_10_1016_j_ijrobp_2016_02_005 crossref_primary_10_1007_s00198_020_05513_x crossref_primary_10_1093_ndt_gft045 crossref_primary_10_1542_peds_2010_0734 crossref_primary_10_1093_wber_lhz024 crossref_primary_10_1136_bmjopen_2022_065591 crossref_primary_10_1080_13696998_2019_1639186 crossref_primary_10_17749_2070_4909_2018_11_4_048_060 crossref_primary_10_2106_JBJS_22_01386 crossref_primary_10_22603_ssrr_2021_0267 crossref_primary_10_1002_ejp_1334 crossref_primary_10_1007_s11325_015_1134_x crossref_primary_10_1007_s40273_017_0565_6 crossref_primary_10_1159_000535638 crossref_primary_10_1038_bjc_2011_390 crossref_primary_10_1111_ner_12035 crossref_primary_10_1016_j_beth_2017_07_001 crossref_primary_10_1016_j_psychres_2018_12_067 crossref_primary_10_1007_s40273_014_0184_4 crossref_primary_10_1007_s10157_023_02357_7 crossref_primary_10_1016_j_jiac_2024_02_001 crossref_primary_10_1016_j_ahj_2020_08_008 crossref_primary_10_1097_ICO_0000000000002242 crossref_primary_10_1016_j_ophtha_2013_02_014 crossref_primary_10_1111_j_1524_4733_2010_00781_x crossref_primary_10_1080_14760584_2024_2323133 crossref_primary_10_1089_jpm_2020_0649 crossref_primary_10_1136_bmjopen_2018_023405 crossref_primary_10_1248_yakushi_130_1725 crossref_primary_10_1016_j_jaad_2024_11_057 crossref_primary_10_1093_mr_roac038 crossref_primary_10_1136_openhrt_2019_001155 crossref_primary_10_1136_bmjopen_2016_012086 crossref_primary_10_1038_s41440_019_0284_9 crossref_primary_10_1111_jep_13681 crossref_primary_10_1016_j_vaccine_2023_04_022 crossref_primary_10_1016_j_spinee_2015_08_025 crossref_primary_10_1177_00469580221081438 crossref_primary_10_1007_s10198_016_0825_y crossref_primary_10_1093_intqhc_mzx109 crossref_primary_10_1097_SLA_0000000000005374 crossref_primary_10_1111_acem_12936 crossref_primary_10_1136_bmjopen_2014_007226 crossref_primary_10_1155_2018_6024698 crossref_primary_10_1371_journal_pone_0189173 crossref_primary_10_1007_s00520_025_09210_5 crossref_primary_10_1097_JCN_0000000000000463 crossref_primary_10_1016_j_jjcc_2016_01_008 crossref_primary_10_2958_suizo_27_185 crossref_primary_10_1016_j_vaccine_2024_05_016 crossref_primary_10_1371_journal_pone_0212366 crossref_primary_10_1016_j_jvs_2013_09_026 crossref_primary_10_1016_S2215_0366_23_00396_6 crossref_primary_10_1080_14737167_2021_1890585 crossref_primary_10_5435_JAAOS_D_21_00166 crossref_primary_10_1253_circj_CJ_22_0086 crossref_primary_10_18553_jmcp_2016_15210 crossref_primary_10_1053_j_oto_2017_09_002 crossref_primary_10_1097_MD_0000000000019379 crossref_primary_10_1038_s41746_022_00702_w crossref_primary_10_1371_journal_pone_0133628 crossref_primary_10_1186_s13023_019_1116_3 crossref_primary_10_3748_wjg_v20_i47_17976 crossref_primary_10_1071_SH10148 crossref_primary_10_1016_j_ypmed_2019_04_011 crossref_primary_10_2139_ssrn_4099416 crossref_primary_10_1289_EHP1370 crossref_primary_10_1007_s40273_013_0110_1 crossref_primary_10_5649_jjphcs_43_610 crossref_primary_10_1016_j_vhri_2021_07_013 crossref_primary_10_1016_j_healthpol_2017_06_001 crossref_primary_10_1007_s00520_022_07102_6 crossref_primary_10_1007_s10198_021_01295_z crossref_primary_10_1111_luts_12122 crossref_primary_10_1007_s10198_019_01034_5 crossref_primary_10_1111_1477_9552_12109 crossref_primary_10_1038_hr_2014_6 crossref_primary_10_1007_s41669_017_0033_4 crossref_primary_10_1080_13696998_2020_1716775 crossref_primary_10_1016_j_dentre_2022_100058 crossref_primary_10_1080_13696998_2020_1804392 crossref_primary_10_1111_jep_12567 crossref_primary_10_36469_9829 crossref_primary_10_1093_cid_civ801 crossref_primary_10_1057_rpm_2012_18 crossref_primary_10_1111_iju_14186 crossref_primary_10_34161_johta_2014_2_1_010 crossref_primary_10_2147_VHRM_S369953 crossref_primary_10_2196_17157 crossref_primary_10_1371_journal_pone_0064275 crossref_primary_10_1186_1472_6963_14_332 crossref_primary_10_1016_j_nec_2019_02_010 crossref_primary_10_1111_jgs_13146 crossref_primary_10_1016_j_vhri_2013_02_009 crossref_primary_10_1007_s12094_014_1170_1 crossref_primary_10_1002_pds_5359 crossref_primary_10_1016_j_wneu_2015_11_062 crossref_primary_10_1002_acr_24514 crossref_primary_10_1016_j_jpsychires_2015_01_019 crossref_primary_10_1016_j_jor_2020_10_003 crossref_primary_10_1007_s12185_024_03905_x crossref_primary_10_1007_s40258_015_0183_4 crossref_primary_10_1080_20016689_2020_1717030 crossref_primary_10_1038_s41433_023_02806_3 crossref_primary_10_1007_s10198_017_0929_z crossref_primary_10_1371_journal_pone_0139140 crossref_primary_10_1016_j_jcpo_2017_03_008 crossref_primary_10_1016_j_vhri_2014_04_009 crossref_primary_10_1097_BRS_0000000000004004 crossref_primary_10_1136_spcare_2022_004069 crossref_primary_10_1007_s11604_024_01640_1 crossref_primary_10_1186_s12888_022_03769_7 crossref_primary_10_1007_s00535_019_01554_0 crossref_primary_10_1016_j_jos_2024_10_003 crossref_primary_10_1136_bmjgh_2023_013070 crossref_primary_10_1186_s12913_019_4281_0 crossref_primary_10_1016_j_acra_2019_09_010 crossref_primary_10_1002_cia2_12163 crossref_primary_10_1097_CORR_0000000000001416 crossref_primary_10_1111_jan_13707 crossref_primary_10_1017_S0266462320000264 crossref_primary_10_1007_s10384_021_00890_0 crossref_primary_10_1016_S1473_3099_10_70219_X crossref_primary_10_1016_j_vhri_2015_06_004 crossref_primary_10_1371_journal_pone_0177848 crossref_primary_10_1017_S0266462319000448 crossref_primary_10_1016_j_archger_2025_105812 crossref_primary_10_1016_j_cgh_2012_12_035 crossref_primary_10_1016_j_jval_2019_10_005 crossref_primary_10_1002_hec_3085 crossref_primary_10_14309_ajg_0000000000000650 crossref_primary_10_1016_j_alit_2021_11_002 crossref_primary_10_1371_journal_pone_0083959 crossref_primary_10_1016_j_jhealeco_2011_09_004 crossref_primary_10_1186_2008_2231_21_40 crossref_primary_10_1016_j_jcrc_2014_10_010 crossref_primary_10_1136_bmjopen_2013_002799 crossref_primary_10_36469_jheor_2018_9781 crossref_primary_10_1007_s40258_015_0204_3 crossref_primary_10_1177_1355819614533675 crossref_primary_10_1002_app5_37 crossref_primary_10_1111_1751_2980_13027 crossref_primary_10_1186_s12962_020_00241_9 crossref_primary_10_3109_14397595_2014_1001475 crossref_primary_10_1186_s13063_018_3038_0 crossref_primary_10_1016_j_vaccine_2014_05_020 crossref_primary_10_1016_j_vhri_2021_06_012 crossref_primary_10_1080_14737167_2023_2295474 crossref_primary_10_1186_s12963_015_0052_2 crossref_primary_10_1097_MD_0000000000012453 crossref_primary_10_1007_s00198_018_4704_5 crossref_primary_10_1007_s10742_021_00246_8 crossref_primary_10_1016_j_bbmt_2016_08_022 crossref_primary_10_1016_j_lungcan_2011_04_002 crossref_primary_10_2337_dc18_0261 crossref_primary_10_1002_pros_24417 crossref_primary_10_1186_s44158_023_00087_6 crossref_primary_10_1093_neuros_nyw081 crossref_primary_10_1080_13696998_2018_1465272 crossref_primary_10_1016_j_jad_2014_08_034 crossref_primary_10_1016_j_vhri_2013_01_007 crossref_primary_10_1007_s00198_021_06010_5 crossref_primary_10_1093_jrr_rrab077 crossref_primary_10_1007_s40121_014_0053_7 crossref_primary_10_1007_s41669_018_0111_2 crossref_primary_10_1136_bmjopen_2015_008123 crossref_primary_10_3111_13696998_2011_644407 crossref_primary_10_1016_j_jid_2020_08_020 crossref_primary_10_1016_j_jad_2012_11_064 crossref_primary_10_1111_jgs_15578 crossref_primary_10_1016_j_vaccine_2013_03_032 crossref_primary_10_1586_14737140_2014_896207 crossref_primary_10_1016_j_jss_2020_05_093 crossref_primary_10_1007_s10157_021_02170_0 crossref_primary_10_1007_s12029_010_9242_0 crossref_primary_10_1177_0194599820948827 crossref_primary_10_3349_ymj_2022_0624 crossref_primary_10_1053_j_jrn_2020_12_008 crossref_primary_10_1016_j_gie_2018_04_2341 crossref_primary_10_1016_j_jos_2019_06_004 crossref_primary_10_1016_j_vaccine_2012_02_033 crossref_primary_10_4244_EIJV9SSA4 crossref_primary_10_1111_ajt_15750 crossref_primary_10_1371_journal_pone_0162679 crossref_primary_10_1136_annrheumdis_2013_205060 crossref_primary_10_1080_14737167_2021_1878881 crossref_primary_10_36469_9781 crossref_primary_10_1002_cam4_6611 crossref_primary_10_3109_17483107_2014_1002540 crossref_primary_10_1186_s13012_018_0834_6 crossref_primary_10_1186_s13104_016_2262_5 crossref_primary_10_1007_s13300_024_01675_7 crossref_primary_10_7133_jca_16_00014 crossref_primary_10_1007_BF03256395 crossref_primary_10_1302_0301_620X_106B6_BJJ_2023_0783_R2 crossref_primary_10_1016_j_vaccine_2020_09_024 crossref_primary_10_1016_j_vaccine_2013_03_052 crossref_primary_10_1371_journal_pone_0153943 crossref_primary_10_1080_24725579_2021_1879321 crossref_primary_10_1016_j_clinthera_2019_07_016 crossref_primary_10_1186_s12916_020_01729_0 crossref_primary_10_1016_j_vhri_2024_101025 crossref_primary_10_1111_acem_13122 crossref_primary_10_1536_ihj_24_194 crossref_primary_10_1016_j_jacep_2016_09_002 crossref_primary_10_1177_00469580211028102 crossref_primary_10_2337_dc11_1643 crossref_primary_10_1016_j_vhri_2020_03_002 crossref_primary_10_2217_pgs_12_124 crossref_primary_10_1259_bjr_20220489 crossref_primary_10_1136_ebmental_2020_300240 crossref_primary_10_1007_s00198_017_3940_4 crossref_primary_10_1186_1478_7547_11_22 crossref_primary_10_2522_ptj_20100239 crossref_primary_10_1007_s00198_019_05258_2 crossref_primary_10_2215_CJN_0000000582 crossref_primary_10_1007_s40273_020_00948_w crossref_primary_10_1186_s12885_021_07889_3 crossref_primary_10_1016_j_ygyno_2017_05_034 crossref_primary_10_1111_obr_12424 crossref_primary_10_1111_j_1553_2712_2011_01008_x crossref_primary_10_1093_jjco_hyae117 crossref_primary_10_1007_s12325_024_02988_6 crossref_primary_10_1016_j_jad_2017_07_018 crossref_primary_10_1016_j_vaccine_2024_02_040 crossref_primary_10_1186_s40780_022_00246_x crossref_primary_10_1186_s11556_022_00310_3 crossref_primary_10_1186_s12962_017_0063_x crossref_primary_10_3820_jjpe_19_91 crossref_primary_10_1080_14737167_2021_1954506 crossref_primary_10_1080_2050571X_2019_1693750 crossref_primary_10_1016_j_ajic_2012_11_015 crossref_primary_10_1016_j_jval_2011_05_030 crossref_primary_10_1136_bmjopen_2018_023082 crossref_primary_10_1097_HJH_0000000000001126 crossref_primary_10_1002_lary_26169 crossref_primary_10_1186_s12960_019_0356_6 crossref_primary_10_1111_hsc_13013 crossref_primary_10_1016_j_jval_2018_07_880 crossref_primary_10_1016_j_prevetmed_2019_104862 crossref_primary_10_1136_heartjnl_2017_312809 crossref_primary_10_3802_jgo_2021_32_e92 crossref_primary_10_1111_nep_12309 crossref_primary_10_1093_milmed_usx112 crossref_primary_10_3390_ijerph20053801 crossref_primary_10_1007_s40136_015_0076_y crossref_primary_10_1016_j_ypmed_2023_107743 crossref_primary_10_1007_s11060_013_1233_0 crossref_primary_10_1111_jiec_12588 crossref_primary_10_1016_j_jad_2020_08_076 crossref_primary_10_1007_s40273_013_0056_3 crossref_primary_10_1111_jan_12577 crossref_primary_10_1002_cam4_2694 crossref_primary_10_3389_fpubh_2018_00168 crossref_primary_10_1016_j_jvacx_2024_100514 crossref_primary_10_1371_journal_pone_0145087 crossref_primary_10_1016_j_vaccine_2019_05_006 crossref_primary_10_1111_coa_12650 crossref_primary_10_1002_alr_22013 crossref_primary_10_3174_ajnr_A7901 crossref_primary_10_1007_s13340_024_00762_1 crossref_primary_10_1016_j_jvacx_2023_100332 crossref_primary_10_3892_mco_2018_1640 crossref_primary_10_1053_j_semss_2017_11_003 crossref_primary_10_1007_s00405_016_4361_2 crossref_primary_10_1080_13696998_2016_1245196 crossref_primary_10_1371_journal_pone_0206203 crossref_primary_10_1007_s10549_010_1243_y crossref_primary_10_1016_j_jval_2014_11_008 crossref_primary_10_1177_1077801211398639 crossref_primary_10_1182_bloodadvances_2019000745 crossref_primary_10_1371_journal_pone_0062614 crossref_primary_10_1007_s40258_013_0031_3 crossref_primary_10_1016_j_clbc_2020_10_007 crossref_primary_10_1002_acr_25022 crossref_primary_10_1002_ijgo_16125 crossref_primary_10_1177_1078155217707335 crossref_primary_10_1186_s40780_014_0006_z crossref_primary_10_1002_deo2_289 crossref_primary_10_1016_j_jval_2020_06_008 crossref_primary_10_1007_s40273_018_0715_5 crossref_primary_10_1111_ajag_12875 crossref_primary_10_1016_j_athoracsur_2022_06_017 crossref_primary_10_1016_j_jval_2019_05_015 crossref_primary_10_1007_s40258_015_0212_3 crossref_primary_10_1186_s13012_016_0406_6 crossref_primary_10_1093_jrr_rrt112 crossref_primary_10_1536_ihj_21_451 crossref_primary_10_1111_cas_13736 crossref_primary_10_1016_j_jval_2020_06_018 crossref_primary_10_1111_j_1553_2712_2010_00957_x crossref_primary_10_1080_13696998_2025_2478755 crossref_primary_10_1371_journal_pone_0172414 crossref_primary_10_1007_s43546_023_00580_8 crossref_primary_10_1080_14737167_2019_1536550 crossref_primary_10_1111_coa_12473 crossref_primary_10_22603_ssrr_2023_0205 crossref_primary_10_1136_acupmed_2012_010178 crossref_primary_10_3389_fvets_2025_1476505 crossref_primary_10_1002_hec_4517 crossref_primary_10_1016_j_arth_2018_02_068 crossref_primary_10_1097_SLA_0000000000001569 crossref_primary_10_1016_j_jval_2012_07_002 crossref_primary_10_2217_cer_15_38 crossref_primary_10_3111_13696998_2010_541045 crossref_primary_10_1002_hep_27315 crossref_primary_10_1080_13696998_2025_2483098 crossref_primary_10_2217_cer_13_95 crossref_primary_10_1007_s11604_024_01665_6 crossref_primary_10_1093_humrep_deac051 crossref_primary_10_7314_APJCP_2014_15_19_8229 crossref_primary_10_1002_jbmr_2784 crossref_primary_10_1177_1403494817746537 crossref_primary_10_1007_s00520_019_04672_w crossref_primary_10_1097_BRS_0000000000001734 crossref_primary_10_1016_j_vaccine_2017_04_046 crossref_primary_10_1016_j_jos_2023_12_004 crossref_primary_10_1093_jjco_hyac107 crossref_primary_10_1111_den_14532 crossref_primary_10_1155_2019_1840894 crossref_primary_10_2196_30690 crossref_primary_10_1186_s12889_018_6356_y crossref_primary_10_3390_curroncol28010060 crossref_primary_10_1080_13696998_2019_1606813 crossref_primary_10_1016_j_jpainsymman_2012_11_007 crossref_primary_10_1016_j_jphys_2020_06_005 crossref_primary_10_1186_s13063_023_07381_2 crossref_primary_10_1186_s12933_020_01145_x crossref_primary_10_1016_j_hrthm_2015_03_061 crossref_primary_10_1002_hep_27316 crossref_primary_10_1016_j_jval_2022_05_004 crossref_primary_10_1080_14397595_2016_1205799 crossref_primary_10_1371_journal_pone_0241697 crossref_primary_10_1186_s12962_020_00213_z crossref_primary_10_1007_s10549_012_1979_7 crossref_primary_10_1016_j_socscimed_2013_02_045 crossref_primary_10_1016_j_apmr_2024_05_007 crossref_primary_10_1016_j_socscimed_2023_115909 crossref_primary_10_1093_heapol_czac069 crossref_primary_10_1016_j_socscimed_2013_05_013 crossref_primary_10_1016_j_socscimed_2018_03_010 crossref_primary_10_1080_14737167_2018_1443810 crossref_primary_10_1038_s41598_022_10665_3 crossref_primary_10_1016_j_juro_2014_11_019 crossref_primary_10_1080_20479700_2017_1336836 crossref_primary_10_1161_STROKEAHA_120_029340 crossref_primary_10_3390_en16020980 crossref_primary_10_1186_s12962_018_0097_8 crossref_primary_10_1038_s44222_024_00185_2 crossref_primary_10_2139_ssrn_2377611 crossref_primary_10_4091_iken_21_233 crossref_primary_10_1080_13696998_2018_1431918 crossref_primary_10_1016_j_socscimed_2010_07_035 crossref_primary_10_1177_1078155213509505 crossref_primary_10_1016_j_jval_2013_06_019 crossref_primary_10_3111_13696998_2015_1006366 crossref_primary_10_1002_jso_26654 crossref_primary_10_1007_s10147_010_0045_x crossref_primary_10_1016_j_msard_2023_104581 crossref_primary_10_1111_iju_13764 crossref_primary_10_1007_s10157_011_0567_1 crossref_primary_10_1016_j_adro_2024_101441 crossref_primary_10_1016_j_techfore_2016_07_041 crossref_primary_10_1016_j_breast_2019_11_012 crossref_primary_10_1248_yakushi_17_00159 crossref_primary_10_1111_den_13250 crossref_primary_10_1136_bmjopen_2012_001884 crossref_primary_10_1097_MLR_0b013e31820192cd crossref_primary_10_1111_all_14268 crossref_primary_10_2139_ssrn_2261511 crossref_primary_10_1111_j_1553_2712_2012_01455_x crossref_primary_10_1186_s12962_023_00487_z crossref_primary_10_3109_09286586_2014_988876 crossref_primary_10_1007_s12403_018_00291_8 crossref_primary_10_1186_1478_7547_11_4 crossref_primary_10_1002_alr_21697 crossref_primary_10_1002_cncr_32753 crossref_primary_10_1080_13696998_2016_1206908 crossref_primary_10_1111_ane_12077 crossref_primary_10_1097_INF_0000000000002938 crossref_primary_10_1371_journal_pone_0189531 crossref_primary_10_1007_s40261_024_01399_3 crossref_primary_10_1016_j_jjcc_2021_10_026 crossref_primary_10_1007_s10198_016_0853_7 crossref_primary_10_1136_bmjopen_2014_006226 crossref_primary_10_1007_s40258_021_00707_8 crossref_primary_10_1038_bjc_2011_101 crossref_primary_10_1016_j_techfore_2012_02_004 crossref_primary_10_1016_j_jval_2011_10_006 crossref_primary_10_1016_S2213_2600_16_30120_5 crossref_primary_10_1016_j_jpsychires_2014_03_002 crossref_primary_10_1371_journal_pone_0266934 crossref_primary_10_52504_001c_7777 crossref_primary_10_1007_s10557_020_07059_w crossref_primary_10_1016_j_ijcard_2011_08_048 crossref_primary_10_1002_ags3_12906 crossref_primary_10_51507_j_jams_2022_15_2_143 crossref_primary_10_1002_hep_27010 crossref_primary_10_3310_hta19140 crossref_primary_10_1007_s40258_016_0246_1 crossref_primary_10_1002_lary_26783 crossref_primary_10_1016_j_amepre_2017_06_004 crossref_primary_10_1093_jjco_hyv186 crossref_primary_10_1111_iwj_12653 crossref_primary_10_1007_s00774_016_0742_2 crossref_primary_10_1371_journal_pone_0123784 crossref_primary_10_1007_s11657_018_0509_6 crossref_primary_10_1007_s12928_017_0488_3 crossref_primary_10_1111_cbdd_12417 crossref_primary_10_1016_j_jad_2016_12_005 crossref_primary_10_1007_s40261_017_0537_9 crossref_primary_10_1007_s00586_016_4835_3 crossref_primary_10_1186_1471_2377_13_56 crossref_primary_10_3820_jjpe_16_1 crossref_primary_10_2500_ajra_2016_30_4297 crossref_primary_10_1007_s00774_015_0663_5 crossref_primary_10_1080_03007995_2016_1222513 crossref_primary_10_1080_03007995_2016_1222512 crossref_primary_10_5649_jjphcs_43_245 crossref_primary_10_1093_jnci_djr303 crossref_primary_10_1123_japa_2019_0085 crossref_primary_10_1007_s10198_021_01364_3 crossref_primary_10_1177_00185787241229152 crossref_primary_10_1016_j_jjcc_2023_06_003 crossref_primary_10_1186_s13063_018_2487_9 crossref_primary_10_3389_fonc_2019_01357 crossref_primary_10_1016_j_vhri_2020_07_579 crossref_primary_10_1093_asj_sjy172 crossref_primary_10_1080_03007995_2021_1971181 crossref_primary_10_3389_fneur_2020_602044 crossref_primary_10_1016_j_dld_2014_06_009 crossref_primary_10_1007_s40258_022_00759_4 crossref_primary_10_1111_resp_13667 crossref_primary_10_4091_iken_24_289 crossref_primary_10_1007_s40258_014_0141_6 crossref_primary_10_1186_s12962_019_0196_1 crossref_primary_10_1136_heartjnl_2016_310195 crossref_primary_10_1007_s11096_022_01410_x crossref_primary_10_1111_jep_14249 crossref_primary_10_1111_1346_8138_15630 crossref_primary_10_1016_j_clinthera_2015_10_007 crossref_primary_10_1177_00185787241267738 crossref_primary_10_1016_j_jvs_2014_03_009 crossref_primary_10_1111_hepr_12570 crossref_primary_10_1186_s12913_018_3234_3 crossref_primary_10_1016_j_vhri_2019_07_004 crossref_primary_10_1007_s40258_018_0424_4 crossref_primary_10_1097_GOX_0000000000006163 crossref_primary_10_1038_kisup_2013_95 crossref_primary_10_1111_vox_13045 crossref_primary_10_1016_j_jval_2017_04_002 crossref_primary_10_1186_s12916_018_1130_7 crossref_primary_10_1016_j_vaccine_2018_07_026 crossref_primary_10_2957_kanzo_55_589 crossref_primary_10_2165_11589270_000000000_00000 crossref_primary_10_1093_jjco_hyae018 crossref_primary_10_1136_bmjgast_2020_000449 |
| Cites_doi | 10.1177/0272989X0002000310 10.1001/archinte.163.14.1637 10.2165/00019053-200119110-00004 10.1002/hec.799 10.1136/bmj.39434.500185.25 10.1037/0278-6133.1.1.61 10.1016/j.jhealeco.2004.12.002 10.1002/hec.864 10.1093/oso/9780198529446.001.0001 10.1177/0272989X05282640 10.1001/jama.1996.03540160061034 |
| ContentType | Journal Article |
| Copyright | Copyright © 2009 John Wiley & Sons, Ltd. Copyright (c) 2009 John Wiley & Sons, Ltd. Copyright Wiley Periodicals Inc. Apr 2010 |
| Copyright_xml | – notice: Copyright © 2009 John Wiley & Sons, Ltd. – notice: Copyright (c) 2009 John Wiley & Sons, Ltd. – notice: Copyright Wiley Periodicals Inc. Apr 2010 |
| DBID | BSCLL AAYXX CITATION OQ6 CGR CUY CVF ECM EIF NPM DKI X2L 7QJ 7X8 |
| DOI | 10.1002/hec.1481 |
| DatabaseName | Istex CrossRef ECONIS Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed RePEc IDEAS RePEc Applied Social Sciences Index & Abstracts (ASSIA) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: DKI name: RePEc IDEAS url: http://ideas.repec.org/ sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1099-1050 |
| EndPage | 437 |
| ExternalDocumentID | 1982951871 wlyhlthec_v_3a19_3ay_3a2010_3ai_3a4_3ap_3a422_437_htm 19382128 634974912 10_1002_hec_1481 HEC1481 ark_67375_WNG_52R8C0JF_1 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Feature |
| GeographicLocations | South Korea United Kingdom--UK Australia United States--US Japan Taiwan |
| GeographicLocations_xml | – name: Taiwan – name: South Korea – name: United Kingdom--UK – name: United States--US – name: Japan – name: Australia |
| GroupedDBID | --- -~X ..I .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1OL 1ZS 31~ 33P 3WU 4.4 44B 4ZD 50Y 50Z 51W 51Y 52M 52O 52Q 52R 52S 52T 52U 52V 52W 53G 5GY 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A04 AABNI AAESR AAHQN AAIPD AAMMB AAMNL AANHP AAONW AAOUF AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABIVO ABJNI ABPVW ABQWH ABSOO ABXGK ACAHQ ACBKW ACBWZ ACCZN ACGFS ACGOF ACHQT ACMXC ACPOU ACRPL ACSCC ACXQS ACYXJ ADBBV ADBTR ADEMA ADEOM ADIZJ ADKYN ADMGS ADNMO ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFKFF AFWVQ AFZJQ AGHNM AGQPQ AGXDD AHBTC AIACR AIDQK AIDYY AIQQE AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ASTYK AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BMXJE BNVMJ BQESF BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-C D-D DCZOG DPXWK DR2 DRFUL DRMAN DRSSH DU5 DUUFO EBD EBS EJD EMOBN EOH F00 F01 F5P FEDTE FUBAC G-S G.N G50 GNP GODZA HBH HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC4 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M67 MEWTI MK4 MRFUL MRMAN MRSSH MSFUL MSMAN MSSSH MXFUL MXMAN MXSSH N04 N06 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2Y P2Z P4B P4C PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WH7 WHWMO WIB WIH WII WIJ WJL WOHZO WQZ WVDHM WXI WXSBR XG1 XV2 YHZ ZZTAW ~IA ~WP AAHHS AARRQ ACCFJ ADZOD AEEZP AEQDE AEUQT AFPWT AFYRF AIFKG AIWBW AJBDE RWI WRC WUP WWH AAYXX CITATION OQ6 CGR CUY CVF ECM EIF NPM - 08R 0R 1AW 31 3N AAPBV AAVGM ABFLS ACJLH ACXME ADDAD ADRMI AFVGU AGJLS AJYWA DKI GA HZ IA IPNFZ NF P4A PQEST RIG WP X X2L Y3 7QJ 7X8 |
| ID | FETCH-LOGICAL-c6371-929204cf65793c423ac20d51abac76b3c6c990557fc1a98bf196a3732cabe1193 |
| IEDL.DBID | DR2 |
| ISSN | 1057-9230 1099-1050 |
| IngestDate | Sun Sep 28 10:38:10 EDT 2025 Sun Sep 28 05:51:45 EDT 2025 Sat Sep 06 22:22:14 EDT 2025 Wed Aug 18 03:10:23 EDT 2021 Wed Feb 19 01:44:53 EST 2025 Sat Mar 08 16:22:19 EST 2025 Tue Jul 01 03:58:09 EDT 2025 Thu Apr 24 23:12:46 EDT 2025 Wed Jan 22 16:26:38 EST 2025 Sun Sep 21 06:21:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright (c) 2009 John Wiley & Sons, Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6371-929204cf65793c423ac20d51abac76b3c6c990557fc1a98bf196a3732cabe1193 |
| Notes | istex:6993CB698163A8B6FED00B964C4255F8F4943A2F ark:/67375/WNG-52R8C0JF-1 ArticleID:HEC1481 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| PMID | 19382128 |
| PQID | 232067027 |
| PQPubID | 31187 |
| PageCount | 16 |
| ParticipantIDs | proquest_miscellaneous_742719467 proquest_miscellaneous_733356671 proquest_journals_232067027 repec_primary_wlyhlthec_v_3a19_3ay_3a2010_3ai_3a4_3ap_3a422_437_htm pubmed_primary_19382128 econis_primary_634974912 crossref_primary_10_1002_hec_1481 crossref_citationtrail_10_1002_hec_1481 wiley_primary_10_1002_hec_1481_HEC1481 istex_primary_ark_67375_WNG_52R8C0JF_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | April 2010 |
| PublicationDateYYYYMMDD | 2010-04-01 |
| PublicationDate_xml | – month: 04 year: 2010 text: April 2010 |
| PublicationDecade | 2010 |
| PublicationPlace | Chichester, UK |
| PublicationPlace_xml | – name: Chichester, UK – name: England – name: York |
| PublicationSeriesTitle | Health Economics |
| PublicationTitle | Health economics |
| PublicationTitleAlternate | Health Econ |
| PublicationYear | 2010 |
| Publisher | John Wiley & Sons, Ltd Wiley-Blackwell Wiley Periodicals Inc |
| Publisher_xml | – name: John Wiley & Sons, Ltd – name: Wiley-Blackwell – name: Wiley Periodicals Inc |
| References | Devlin N, Parkin D. 2004. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 13: 437-452. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. 2003. What is the price of life and why doesn't it increase at the rate of inflation? Archives of Internal Medicine 163: 1637-1641. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. 2000. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making 20: 332-342. George B, Harris A, Mitchell A. 2001. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19: 1103-1109. Turnbull BW. 1976. The empirical distribution function from arbitarily grouped, censored and truncated data. Journal of Royal Statistical Society Series B 38: 290-295. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart G. 2005. Methods for the Economic Evaluation of Health Care Programmes (3rd edn). Oxford University Press: New York. King Jr JT, Tsevat J, Lave JR, Roberts MS. 2005. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Medical Decision Making 25: 667-677. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. 2008. Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal 336: 251-254. Glick HA, Doshi J, Sonnad S, Polsky D. 2006. Economic Evaluation in Clinical Trials. Oxford University Press: New York. Gyrd-Hansen D. 2003. Willingness to pay for a QALY. Health Econnomics 12: 1049-1060. Laupacis A, Feeny D, Detsky AS, Tugwell PX. 1992. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 146: 473-481. Kaplan RM, Bush JW. 1982. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1: 61-80. Siegel JE, Weinstein MC, Russell LB, Gold MR. 1996. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. Journal of American Medical Association 276: 1339-1341. Basu A, Meltzer D. 2005. Implications of spillover effects within the family for medical cost-effectiveness analysis. Journal of Health Econnomics 24: 751-773. 1982; 1 1992; 146 2004; 13 2000; 20 2001; 19 2008 2007 2006 2008; 336 2005 1996; 276 1976; 38 2005; 24 2003; 12 2005; 25 2003; 163 e_1_2_1_8_1 Laupacis A (e_1_2_1_12_1) 1992; 146 e_1_2_1_5_1 Glick HA (e_1_2_1_7_1) 2006 e_1_2_1_6_1 Turnbull BW (e_1_2_1_17_1) 1976; 38 e_1_2_1_3_1 e_1_2_1_4_1 e_1_2_1_13_1 e_1_2_1_10_1 e_1_2_1_2_1 e_1_2_1_11_1 e_1_2_1_16_1 e_1_2_1_14_1 e_1_2_1_15_1 e_1_2_1_9_1 e_1_2_1_18_1 |
| References_xml | – reference: Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. 2000. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making 20: 332-342. – reference: Ubel PA, Hirth RA, Chernew ME, Fendrick AM. 2003. What is the price of life and why doesn't it increase at the rate of inflation? Archives of Internal Medicine 163: 1637-1641. – reference: Basu A, Meltzer D. 2005. Implications of spillover effects within the family for medical cost-effectiveness analysis. Journal of Health Econnomics 24: 751-773. – reference: King Jr JT, Tsevat J, Lave JR, Roberts MS. 2005. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Medical Decision Making 25: 667-677. – reference: Devlin N, Parkin D. 2004. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 13: 437-452. – reference: Laupacis A, Feeny D, Detsky AS, Tugwell PX. 1992. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 146: 473-481. – reference: Siegel JE, Weinstein MC, Russell LB, Gold MR. 1996. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. Journal of American Medical Association 276: 1339-1341. – reference: George B, Harris A, Mitchell A. 2001. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19: 1103-1109. – reference: Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. 2008. Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal 336: 251-254. – reference: Kaplan RM, Bush JW. 1982. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1: 61-80. – reference: Glick HA, Doshi J, Sonnad S, Polsky D. 2006. Economic Evaluation in Clinical Trials. Oxford University Press: New York. – reference: Gyrd-Hansen D. 2003. Willingness to pay for a QALY. Health Econnomics 12: 1049-1060. – reference: Turnbull BW. 1976. The empirical distribution function from arbitarily grouped, censored and truncated data. Journal of Royal Statistical Society Series B 38: 290-295. – reference: Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart G. 2005. Methods for the Economic Evaluation of Health Care Programmes (3rd edn). Oxford University Press: New York. – volume: 19 start-page: 1103 year: 2001 end-page: 1109 article-title: Cost‐effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996) publication-title: Pharmacoeconomics – volume: 336 start-page: 251 year: 2008 end-page: 254 article-title: Value based pricing for NHS drugs: an opportunity not to be missed? publication-title: British Medical Journal – year: 2005 – volume: 38 start-page: 290 year: 1976 end-page: 295 article-title: The empirical distribution function from arbitarily grouped, censored and truncated data publication-title: Journal of Royal Statistical Society Series B – year: 2008 – year: 2007 – volume: 163 start-page: 1637 year: 2003 end-page: 1641 article-title: What is the price of life and why doesn't it increase at the rate of inflation? publication-title: Archives of Internal Medicine – year: 2006 – volume: 20 start-page: 332 year: 2000 end-page: 342 article-title: Willingness to pay for a quality‐adjusted life year: in search of a standard publication-title: Medical Decision Making – volume: 25 start-page: 667 year: 2005 end-page: 677 article-title: Willingness to pay for a quality‐adjusted life year: implications for societal health care resource allocation publication-title: Medical Decision Making – volume: 276 start-page: 1339 year: 1996 end-page: 1341 article-title: Recommendations for reporting cost‐effectiveness analyses. Panel on Cost‐Effectiveness in Health and Medicine publication-title: Journal of American Medical Association – volume: 24 start-page: 751 year: 2005 end-page: 773 article-title: Implications of spillover effects within the family for medical cost‐effectiveness analysis publication-title: Journal of Health Econnomics – volume: 12 start-page: 1049 year: 2003 end-page: 1060 article-title: Willingness to pay for a QALY publication-title: Health Econnomics – volume: 146 start-page: 473 year: 1992 end-page: 481 article-title: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations publication-title: Canadian Medical Association Journal – volume: 1 start-page: 61 year: 1982 end-page: 80 article-title: Health‐related quality of life measurement for evaluation research and policy analysis publication-title: Health Psychology – volume: 13 start-page: 437 year: 2004 end-page: 452 article-title: Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis publication-title: Health Economics – ident: e_1_2_1_14_1 – ident: e_1_2_1_9_1 doi: 10.1177/0272989X0002000310 – ident: e_1_2_1_18_1 doi: 10.1001/archinte.163.14.1637 – ident: e_1_2_1_6_1 doi: 10.2165/00019053-200119110-00004 – ident: e_1_2_1_8_1 doi: 10.1002/hec.799 – ident: e_1_2_1_3_1 doi: 10.1136/bmj.39434.500185.25 – volume-title: Economic Evaluation in Clinical Trials year: 2006 ident: e_1_2_1_7_1 – volume: 38 start-page: 290 year: 1976 ident: e_1_2_1_17_1 article-title: The empirical distribution function from arbitarily grouped, censored and truncated data publication-title: Journal of Royal Statistical Society Series B – ident: e_1_2_1_13_1 – ident: e_1_2_1_10_1 doi: 10.1037/0278-6133.1.1.61 – ident: e_1_2_1_2_1 doi: 10.1016/j.jhealeco.2004.12.002 – ident: e_1_2_1_4_1 doi: 10.1002/hec.864 – ident: e_1_2_1_5_1 doi: 10.1093/oso/9780198529446.001.0001 – ident: e_1_2_1_11_1 doi: 10.1177/0272989X05282640 – ident: e_1_2_1_16_1 doi: 10.1001/jama.1996.03540160061034 – ident: e_1_2_1_15_1 – volume: 146 start-page: 473 year: 1992 ident: e_1_2_1_12_1 article-title: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations publication-title: Canadian Medical Association Journal |
| SSID | ssj0009906 |
| Score | 2.4936976 |
| SecondaryResourceType | review_article |
| Snippet | Although the threshold of cost effectiveness of medical interventions is thought to be £20 000–£30 000 in the UK, and $50 000–$100 000 in the US, it is well... Although the threshold of cost effectiveness of medical interventions is thought to be 20 000- 30 000 UK pounds in the UK, and $50 000-$100 000 in the US, it... Although the threshold of cost effectiveness of medical interventions is thought to be £20 000-£30 000 in the UK, and $50 000-$100 000 in the US, it is well... Although the threshold of cost effectiveness of medical interventions is thought to be L20 000-L30 000 in the UK, and $50 000-$100 000 in the US, it is well... Although the threshold of cost effectiveness of medical interventions is thought to be (pound sterling)20 000-(pound sterling)30 000 in the UK, and $50... |
| SourceID | proquest repec pubmed econis crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 422 |
| SubjectTerms | Adult Attitude to Health Australia Choice Behavior Cost analysis Cost effectiveness Cost-Benefit Analysis cost-effectiveness analysis Decision making Developed Countries double-bound dichotomous choice Female Financing, Personal Health Care Costs Health care expenditures Health Care Surveys Health economics Health status Humans International comparisons Internationality Japan Male Manycountries Middle Aged Models, Econometric QALY Quality adjusted life years Quality of life Scientific evidence Studies Surveys and Questionnaires Taiwan threshold Thresholds Willingness to pay WTP Young Adult |
| Title | International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? |
| URI | https://api.istex.fr/ark:/67375/WNG-52R8C0JF-1/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhec.1481 http://www.econis.eu/PPNSET?PPN=634974912 https://www.ncbi.nlm.nih.gov/pubmed/19382128 http://econpapers.repec.org/article/wlyhlthec/v_3a19_3ay_3a2010_3ai_3a4_3ap_3a422-437.htm https://www.proquest.com/docview/232067027 https://www.proquest.com/docview/733356671 https://www.proquest.com/docview/742719467 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbQhBAS4jIuC4PJSIjLQ7bEduKEFzSVlTJggmnThniwHNeh1UZbJelKeYJ_wG_kl3BsJ6mKBkI8OJbikza2zzn-bB9_QeghUzCKqID6RLG-z7I48gFV930ZpIrxhAZBbtk-9-LeIds9jo7rqEpzFsbxQ7QLbsYyrL82Bi6zcmtBGjrQCszcnroOaWxo81_sL5ijwMnag0UAR3zAMEHDOxuQrebBpZHoopl-DkuAqKZ1v5yHN6Gs0BOtlmGsHYe619DHpgYu_ORkc1plm-rrb-SO_1fF6-hqDU_xttOnG-iCHq2iS2_rDfhVdMUt82F3eukm-r60oojLaXGm53g8wrOhJfs2jvTntx_VGC4TOcdPjg7ePcUAlEFGYxPMVD_5fvvNB_xJwp_0n-HZQFZ4WGIAp5AKXZo9MjzOsRqXFXYhKLWXfn4LHXZ3Djo9v_6qg69iykPojZQETOVxBK5BAZozJJH9KJSZVDzOqIoVdF4U8VyFMk2yHHyEpJwSJTMdAt68jVZG8I5rCCspiUw41XmiWMSllDD9kqkiGaBIMH8PPW56WKia8tx8eeNUOLJmIqCFhWlhDz1oJSeO5uMcmTWnJK1ETBlMx9KQeOiRVZu2RBYnJmKOR-Jo76WIyH7SCXa7An5jvdErUTuLUgCoNaelCPcQbkvBys3WjRzp8bQUnFIKwJuHfxFhhIcpjHseuuMUdlGTlCYAURIPdawGtwWz0_kAtAXunAkqwxQuc0gmQgKyISQGaWJyQgSjXAyqz1BZq7R_bCjR2-mY_O6_Cq6jyy4owwRE3UMrVTHV9wHrVdkGWPXrVxvWtn8Bf59PSw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLamgQAJcRmXhXExEuLykC2xnTiBBzSVlTK6CqZOGxKS5bgOrTbaqklXyhP8A34jv4TjOElVNBDiwbEUn7Sxfc7xZ_v4C0KPmIJRRHnUJYr1XJaEgQuouudKL1aMR9Tz0oLtsxO2DtjuUXC0gl5UZ2EsP0S94GYso_DXxsDNgvTWgjW0rxXYuTl2fc5szxmrfLW_4I4CN1scLQJA4gKK8SrmWY9sVU8ujUXnzQR0kAFINe375SzECWUTPdZqGcgWI1HzKvpY1cEGoBxvTvNkU339jd7xPyt5DV0pESretip1Ha3o4Rq6sFfuwa-hy3alD9sDTDfQ96VFRZxNJ6d6jkdDPBsUfN_Gl_789iMfwWUs5_jpYffdMwxYGWQ0NvFM5ZPvt9sf8CcJf9J7jmd9meNBhgGfQprozGyT4VGK1SjLsY1CKR31y5vooLnTbbTc8sMOrgop96E7YuIxlYYBeAcFgM7wRPYCXyZS8TChKlTQe0HAU-XLOEpScBOSckqUTLQPkPMWWh3CO64jrKQkMuJUp5FiAZdSwgxMxookACTBAzjoSdXFQpWs5-bjGyfC8jUTAS0sTAs76GEtObZMH2fIrFstqSVCymBGFvvEQY8LvalL5OTYBM3xQBx2XouA7EcNb7cp4Dc2KsUSpb_IBOBac2CKcAfhuhQM3ezeyKEeTTPBKaWAvbn_FxFGuB_D0Oeg21ZjFzWJaQQoJXJQo1DhumB2Mu-DtsCdU0GlH8NlDskESUA2gMQgjU1OiGCUi37-GSpbaO0fG0q0dhomv_Ovgg_QxVZ3ry3abzpvN9AlG6Nh4qPuotV8MtX3APrlyf3CxH8BZSVSbw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbQQBPSxGXAFsbFSIjLQ7bEduKEFzSVlTJGNaZNG-LBclyHVhtt1KQr5Qn-Ab-RX8JxnKQqGgjx4FiKT9rYPuf4s338BaHHTMEoojzqEsV6LkvCwAVU3XOlFyvGI-p5acn22Q07R2z3JDipoirNWRjLD9EsuBnLKP21MfCsl27NSUP7WoGZm1PXl1kIkysDiA7m1FHgZcuTRYBHXAAxXk0865Gt-smFoeiKmX8OcsCopnm_XAQ4oWysM60WcWw5ELWvo491FWz8yenmpEg21dff2B3_r4430LUKn-Jtq1A30SU9XEXL76od-FW0Ytf5sD2-dAt9X1hSxPlkfK5neDTE00HJ9m086c9vP4oRXDI5w8-OD_efY0DKIKOxiWaqnny_vfcBf5LwJ70XeNqXBR7kGNAppLHOzSYZHqVYjfIC2xiUyk2_vI2O2juHrY5bfdbBVSHlPvRGTDym0jAA36AAzhmWyF7gy0QqHiZUhQo6Lwh4qnwZR0kKTkJSTomSifYBcN5BS0N4x3WElZRERpzqNFIs4FJKmH_JWJEEYCTYv4Oe1j0sVMV5bj69cSYsWzMR0MLCtLCDHjWSmeX5uEBm3SpJIxFSBvOx2CcOelKqTVMix6cmZI4H4rj7WgTkIGp5u20Bv7FR65WovEUuANWa41KEOwg3pWDmZu9GDvVokgtOKQXkzf2_iDDC_RgGPgetWYWd1ySmEWCUyEGtUoObgunZrA_aAnfOBZV-DJcZJBMiAdkAEoOUmZwQwSgX_eIzVLZU2j82lOjstEx-918FH6Ll_Vdtsfem-3YDXbUBGiY46h5aKsYTfR9wX5E8KA38Fy4YUR4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+survey+on+willingness-to-pay+%28WTP%29+for+one+additional+qaly+gained&rft.jtitle=Health+economics&rft.date=2010-04-01&rft.pub=Wiley-Blackwell&rft.issn=1057-9230&rft.volume=19&rft.issue=4&rft.spage=422&rft.epage=437&rft_id=info:doi/10.1002%2Fhec.1481&rft.externalDocID=634974912 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1057-9230&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1057-9230&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1057-9230&client=summon |